Physician profile
Daniel E Lee
NPI 1578503132
$96,072.52
in general payments reported to CMS, 2019-2025
13 companies · $2,294 in 2025
The $2,294 reported for 2025 was more than what 97% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $80K · 2020: $12K · 2021: $475 · 2022: $228 · 2023: $718 · 2024: $1,047 · 2025: $2,294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,021 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,820 · Travel and Lodging: $217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,021.49 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,820.00 |
| Travel and Lodging | $217.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $91,018.62 | 2019-2025 | Dovato, Cabenuva |
| Becton, Dickinson and Company | $1,820.00 | 2025 | |
| Emd Serono, INC. | $1,437.55 | 2020-2024 | Serostim |
| Merck Sharp & Dohme LLC | $927.61 | 2019-2023 | |
| Theratechnologies INC. | $251.29 | 2019-2025 | Egrifta, Trogarzo |
| Glaxosmithkline, LLC. | $170.22 | 2019 | |
| Motiva USA, LLC | $162.95 | 2025 | |
| Lilly USA, LLC | $78.61 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.74 | 2024-2025 | Xifaxan |
| Janssen Scientific Affairs, LLC | $44.79 | 2023 | |
| Pulmonx Corporation | $39.59 | 2025 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Gilead Sciences, INC. | $26.08 | 2021 | |
| Napo Pharmaceuticals INC | $25.47 | 2024 | Mytesi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.